Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Oct 5;29(157):200310.
doi: 10.1183/16000617.0310-2020. Print 2020 Sep 30.

Guidance production before evidence generation for critical issues: the example of COVID-19

Nicolas Roche  1 , Thomy Tonia  2 , Andrew Bush  3 , Chris Brightling  4 , Martin Kolb  5   6 , Anh Tuan Dinh-Xuan  7 , Marc Humbert  8 , Anita Simonds  9 , Yochai Adir  10
Affiliations
Editorial

Guidance production before evidence generation for critical issues: the example of COVID-19

Nicolas Roche et al. Eur Respir Rev. .

Abstract

Production of guidance in rapidly evolving areas where evidence is absent or fragile is challenging and needs to use rigorous methods interpreted with caution https://bit.ly/3jpChqk

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: N. Roche has nothing to disclose. Conflict of interest: T. Tonia is a European Respiratory Society Methodologist. Conflict of interest: A. Bush has nothing to disclose. Conflict of interest: C. Brightling has nothing to disclose. Conflict of interest: M. Kolb reports grants from the Canadian Pulmonary Fibrosis Foundation, Canadian Institute for Health Research, Alkermes and Actelion; other funding from Roche, Boehringer Ingelheim and European Respiratory Journal; grants and other funding from Pulmonary Fibrosis Foundation; grants and personal fees from Boehringer Ingelheim, Roche Canada and Prometic; and personal fees from Gilead, outside the submitted work. Conflict of interest: A-T. Dinh-Xuan has nothing to disclose. Conflict of interest: M. Humbert reports grants, personal fees and non-financial support from GlaxoSmithKline; personal fees from AstraZeneca, Novartis, Roche, Sanofi, Teva and Merck; and grants and personal fees from Acceleron, Actelion and Bayer, outside the submitted work. Conflict of interest: A. Simonds has nothing to disclose. Conflict of interest: Y. Adir has nothing to disclose.

References

    1. Khalifa SAM, Mohamed BS, Elashal MH, et al. Comprehensive overview on multiple strategies fighting COVID-19. Int J Environ Res Public Health 2020; 17: 5813. - PMC - PubMed
    1. Macera M, De Angelis G, Sagnelli C, et al. Clinical presentation of COVID-19: case series and review of the literature. Int J Environ Res Public Health 2020; 17: 5062. doi: 10.3390/ijerph17145062 - DOI - PMC - PubMed
    1. Calabrese F, Pezzuto F, Fortarezza F, et al. Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists. Virchows Arch 2020; 477: 359–372. doi: 10.1007/s00428-020-02886-6 - DOI - PMC - PubMed
    1. Akca UK, Kesici S, Ozsurekci Y, et al. Kawasaki-like disease in children with COVID-19. Rheumatol Int 2020; in press [ 10.1007/s00296-020-04701-6]. - DOI - PMC - PubMed
    1. Potus F, Mai V, Lebret M, et al. Novel insights on the pulmonary vascular consequences of COVID-19. Am J Physiol Lung Cell Mol Physiol 2020; 319: L277–L288. doi: 10.1152/ajplung.00195.2020 - DOI - PMC - PubMed

Publication types